Overview
Indications
KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
Contraindications
When this intervention should not be used
KEVEYIS is contraindicated in the following circumstances: Warnings and Precautions (5.1) [see] Hypersensitivity to dichlorphenamide or other sulfonamides Warnings and Precautions (5.2) Drug Interactions (7.1) [seeand] Concomitant use of KEVEYIS and high dose aspirin Warnings and Precautions (5.4) [
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
Clinical Trials
136 trials linked to this intervention
Recent Trials
Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
Effect of Age on Latanoprost 0.005% in Patients With Glaucoma
Effects of Intravenous Clonidine on Ocular Blood Flow and Intraocular Pressure
Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Specialists
Providers who commonly manage this intervention
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Diclofenamide (substance)
- SNOMED CT
- 387111009
- UMLS CUI
- C0012086
- RxNorm CUI
- 3353
- Labeler
- Xeris Pharmaceuticals, Inc.
Clinical Data
This intervention maps to 4 entities in the Ltrl knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.